Reframe (Glucobit)
-79%
est. 2Y upside i
App to help people quit or cut back on alcohol use
Rank
#3889
Sector
Digital Health
Est. Liquidity
~3Y
Data Quality
Data: LowThe equity upside for a new employee is deeply negative with an expected return of -78.6% over 2 years.
Last updated: July 3, 2026
Even with a strong exit multiple of 5.5x on projected revenue, the high entry multiple leads to negative returns; after 20% dilution, upside is -39.7%.
Multiple contraction to 4x and low growth yield -41.6% before dilution; after 20% dilution, -61.6%.
Exit below total funding ($24.7M) wipes out common stock; preference stack absorbs all value.
Preference Stack Risk
highFunding Intensity
2470%Total funding of $24.7M represents 24.7% of the $100M valuation, giving preferred investors a significant claim ahead of common stock.
Dilution Risk
highWith the last round over 4 years ago and $24.7M total funding, a new raise is probable, causing 15-25% dilution per round.
Secondary Liquidity
noneNo secondary market activity indicated; employees likely have no liquidity options until a liquidity event.
Questions to Ask at the Interview
Strategic questions based on Reframe (Glucobit)'s data — designed to show you've done your homework.
- 1
“How does Reframe plan to accelerate revenue growth beyond 9% given market saturation and competition from incumbents?”
- 2
“What is the company's strategy to address the data breach fallout and regain user trust?”
- 3
“As an early employee, what is the expected path to liquidity and how does the company view secondary market opportunities?”
Community
Valuation Sentiment
Our model estimates -79% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.